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Abstract
Background: Jeff is a dominant mouse mutant displaying chronic otitis media. The gene underlying
Jeff is Fbxo11, a member of the large F-box family, which are specificity factors for the SCF E3
ubiquitin ligase complex. Jeff  homozygotes die shortly after birth displaying a number of
developmental abnormalities including cleft palate and eyes open at birth. TGF-b signalling is
involved in a number of epithelial developmental processes and we have investigated the impact of
the Jeff mutation on the expression of this pathway.
Results: Phospho-Smad2 (pSmad2) is significantly upregulated in epithelia of Jeff homozygotes.
Moreover, there was a significant increase in nuclear localization of pSmad2 in contrast to wild type.
Mice heterozygous for both Jeff and Smad2 mutations recapitulate many of the features of the Jeff
homozygous phenotype. However, tissue immunoprecipitations failed to detect any interaction
between Fbxo11 and Smad2. Fbxo11 is known to neddylate p53, a co-factor of pSmad2, but we did
not find any evidence of genetic interactions between Jeff and p53 mutants. Nevertheless, p53 levels
are substantially reduced in Jeff mice suggesting that Fbxo11 plays a role in stabilizing p53.
Conclusion: Overall, our findings support a model whereby Fbxo11, possibly via stabilization of
p53, is required to limit the accumulation of pSmad2 in the nucleus of epithelial cells of palatal
shelves, eyelids and airways of the lungs. The finding that Fbxo11 impacts upon TGF-b signalling has
important implications for our understanding of the underlying disease mechanisms of middle ear
inflammatory disease.
Background
Otitis media (OM), inflammation of the middle ear, is the
most common cause of hearing impairment in children,
potentially causing language delays and learning and
behavioural disruption [1,2]. A significant number of
children with acute OM will go on to develop OM with
effusion or chronic OM. The high prevalence of the dis-
ease, coupled with its recurrent and chronic nature,
accounts for the large number of tympanostomies, the
insertion of ventilation tubes or 'grommets' in the tym-
panic membrane, undertaken in affected children. OM is
still the most common cause of surgery in children in the
developed world. However, this and other treatments are
largely ineffective.
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There is evidence from studies of the human population
that there is a significant genetic component predisposing
to recurrent or chronic OM [3-5], yet little is known about
the underlying genetic pathways involved. From a deaf-
ness screen as part of the MRC Harwell mouse mutagene-
sis programme [6] we have identified two novel dominant
mutants, Jeff and Junbo, which develop a conductive deaf-
ness due to a chronic suppurative OM [7-9]. Both these
mutants represent the first models for chronic forms of
middle ear inflammatory disease in humans, and both of
these mutants have now been cloned [8,9].
The gene underlying the Jeff  mutant was identified as
Fbxo11, a member of the F-box family [8]. The Jeff mutant
carries a non-conservative glutamine to leucine change at
amino acid 491. F-box proteins function as part of an SCF
(SKP1-cullin-F-box) E3 protein ligase complex, recogniz-
ing and binding phosphorylated proteins and promoting
their ubiquitination and degradation [10,11]. However,
the substrate of Fbxo11 is unknown. It has been demon-
strated that Caenorhabditis elegans DRE-1, an orthologue of
human FBXO11, and the SKP1-like homologue SKR-1
function as part of an E3 ligase complex, as does its
human counterpart [12]. There is also evidence that
FBXO11 has arginine methyltransferase activity, catalyz-
ing arginine methylation, but with a structure different
from all other known protein arginine methyltransferases
(PRMTs) [13]. PRMT activity was not however detected for
DRE-1 [12]. Recently it has been demonstrated that
FBXO11 can function as a Nedd8-ligase for the tumour
suppressor protein p53, promoting the neddylation of
p53 and inhibiting its transcriptional activity [14]. p53 is
a partner of Smad2 in the activation of multiple trans-
forming growth factor b (TGF-b) target genes [15].
We previously reported that mice homozygous for the Jeff
mutation die within a few hours of birth [8]. Newborn Jeff
homozygotes have cleft palate, facial clefting, impairment
of respiratory function and an eyes-open at birth (EOB)
phenotype [8]. TGF-b signalling has been shown to be
involved in all of these processes [16-18]. For these rea-
sons it will be important to understand the role of Fbxo11
in mouse developmental processes and in particular the
impact of mutations on the TGF-b signalling pathway.
The TGF-b superfamily is composed of a large number of
cytokines involved in a variety of cellular processes such as
proliferation, differentiation, epithelial mesenchymal
transformation and apoptosis [19,20]. They mediate their
effects from membrane to nucleus through combinations
of type I and type II serine/threonine kinase receptors
(TGFbR-I and TGFbR-II) and their downstream effectors,
Smad proteins. Certain receptor-regulated Smads (R-
Smads) become phosphorylated by activated type I recep-
tors and form a heteromeric complex with a common-
partner Smad4. Once formed, this R-Smad/Smad4 com-
plex translocates to the nucleus and, in conjunction with
other nuclear cofactors, regulates the transcription of tar-
get genes [19]. Two different Smad signalling branches
have been described. The TGF-b sub-family ligands TGF-b,
Activins and Nodals, are transduced by Smad2 and
Smad3. In contrast, BMP sub-family ligands are trans-
duced by Smad1, Smad5 and Smad8 [19].
TGF-b signalling is controlled by many mechanisms,
including ubiquitin-mediated proteosomal degradation
[19,21,22]. A key component of ubiquitination, the ubiq-
uitin ligase (E3), controls the specificity and timing of
Smad ubiquitination. The E3 ubiquitin ligases, Smad
ubiquitination-related factor 1 and 2 (Smurf1 and 2),
have been identified as regulators of TGF-b signalling tar-
geting Smad1 for ubiquitination and degradation [23,24].
At higher expression levels, Smurf2 also lowers protein
levels of Smad2, but not Smad3 [24]. In addition to regu-
lation of steady-state levels of R-Smads, the ubiquitin-pro-
teosome pathway is also involved in the degradation of
activated R-Smads [21,22]. Smurf2 exhibits higher bind-
ing affinity to activated Smad2 upon TGF-b stimulation,
and Smurf2 is a candidate E3 ligase for activated Smad2
degradation [25]. Roc1, a component of an SCF complex,
interacts and promotes degradation of activated Smad3
[26]. MFB-1, a novel F-box-type ubiquitin ligase, nega-
tively regulates Dauer formation in C. elegans by modulat-
ing DAF-7/TGF-b-like signalling pathway [27]. More
recently, Arkadia, a RING-domain E3 ubiquitin ligase, has
been shown to interact with and ubiquitinate phospho-
Smad2/3 [28]. At the same time, Arkadia enhances tran-
scription, thus coupling turnover of phospho-Smad2/3 to
activity.
We have set out to explore the role of Fbxo11 in develop-
ment and to relate the Jeff homozygous mutant pheno-
type to the underlying mechanisms of Fbxo11 function.
Given the findings of a palatal and EOB phenotype in Jeff
mice and the role of TGF-b signalling in these processes,
we have focused our studies on salient members of the
TGF-b family signalling pathway and demonstrated that
pSmad2 is upregulated in the epithelia of Jeff homozy-
gotes. Moreover, we have utilized compound mutants to
assess genetic interactions and throw light on the genetic
pathways affected. Mice heterozygous for both Jeff and
Smad2 mutations recapitulate the Jeff homozygote pheno-
type in the palate and lungs. However, we failed to detect
any interaction between Fbxo11  and Smad2, suggesting
they are indirect partners in the development of these tis-
sues. Our observations support a model whereby in pal-
ate, eyelid and lung Fbxo11-dependent modification is
required to limit the accumulation of pSmad2 in the
nucleus of epithelial cells of palatal shelves, eyelids and
airways of the lungs. Overall, we conclude that Fbxo11 isPathoGenetics 2009, 2:5 http://www.pathogeneticsjournal.com/content/2/1/5
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involved with the regulation of TGF-b signalling, a finding
that has implications for the chronic middle ear inflam-
matory phenotype that is observed in Jeff heterozygotes.
Results
Jeff homozygote mutant mice develop a variety of epithe-
lial developmental abnormalities, including palatal and
EOB phenotypes. We used immunohistochemistry (IHC)
to study protein expression and localization of members
of the TGF-b signalling pathway (TGFb-3, TGFbR-I,
Smad2, Smad3 and Smad4) in Jeff mutants in both palatal
and eye tissues at relevant developmental stages. Given
the apparent involvement of Fbxo11 in epithelial devel-
opment, we also investigated the expression of these TGF-
b signalling pathway members in lung development.
Palatal expression in Jeff mutants
Jeff homozygote palatal shelves start to grow and lift on
time, but they fail to fuse at the right developmental stage
(Figure 1a) and homozygote mice are born with cleft pal-
ate (Figure 1b). This is reminiscent of TGF-b3 mutant
mice [29]. To characterize the distribution pattern of TGF-
b ligands, TGF-b receptors and Smads in the developing
palates, we examined embryonic heads from wild-type
and homozygote Jeff (Jf/Jf) mice by IHC (Figure 2). The
result revealed one major difference in the pattern and
localization of pSmad2. In wild types at embryonic day
15.5 (E15.5), as the midline epithelial seam was disrupted
and medial edge epithelium (MEE) disappeared, pSmad2
was largely confined to the oral/nasal triangle area as a
nuclear and cytoplasmic stain (Figure 2b). In contrast, in
Jf/Jf mice at E15.5 an increased number of epithelial cells
are positive for pSmad2 in the palatal shelves concen-
trated to the tip of the palatal epithelium and the oral/
nasal palatal epithelial cells (Figure 2b). Moreover, in Jf/Jf
palates at E15.5 pSmad2 was present as a nuclear stain in
the majority of the cells. In homozygote mice 57% of epi-
thelial cells in the palate showed a nuclear localization of
pSmad2, compared with 27% in wild-type mice (P  =
0.000255). There was a commensurate significant
decrease in cells showing a cytoplasmic localization in Jf/
Jf mice compared with wild-type mice. TGF-b3, TGFbR-I,
TGFbR-II, Smad2, Smad4, Smurf2 and also Fbox11, in
both wild-type and Jf/Jf mice, were localized to the cyto-
plasm of the epithelial cells (Figure 2a and Additional file
1). There was no difference in the distribution of activated
Smad2 in wild-type and homozygote palates before the
fusion (E14.5) (Figure 2b).
TGF-b3 has been implicated to inhibit MEE proliferation
during palatal fusion [30]. We used Ki67 as a marker for
proliferation and examined E14.5 (data not shown) and
Cleft palate phenotype Figure 1
Cleft palate phenotype. a. Coronal sections through the palate of E14.5 (before the fusion) and E15.5 (after the fusion) 
wild-type (WT) and homozygote (Jf/Jf) embryos, haematoxylin-eosin stained. Scale bars 200 mm. b. Cross-sections of heads 
showing secondary palate of a wild-type (WT) newborn mouse with fused palate and a homozygote (Jf/Jf) newborn mouse with 
a cleft (arrow).
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E15.5 palates using IHC. We were unable to detect any sig-
nificant differences in staining patterns along the MEE
between Jf/Jf palatal tissues and wild-type mice (Figure
2c). There are three cellular fates for the MEE: epithelial-
mesenchymal transformation, migration and pro-
grammed cell death. We used a cleaved caspase-3 anti-
body to compare cells undergoing apoptosis in E15.5
wild-type and homozygote palates. The results indicate
that there are fewer apoptotic cells in Jf/Jf E15.5 palates (P
= 0.017547) (Figure 2c), most likely reflecting the absence
of shelf fusion that is followed by MEE disintegration.
Eyelid expression in Jeff mutants
Jeff homozygous mutant eyelids start to grow on time, but
fail to fuse at the correct developmental stage and the mice
have an EOB phenotype (Figures 3a and 3b). We have
applied the same panel of antibodies used on the palates
to sections of E16 eyelids from both wild-type and Jf/Jf
mice. These studies revealed similar results to those
observed on palates. The majority of localization of
pSmad2 in wild-type E16 eyelids was cytoplasmic. The
staining was confined to the epidermis only (Figure 4b).
In Jf/Jf mice more cells are positive for pSmad2 than in
Immunolocalization in palate tissue Figure 2
Immunolocalization in palate tissue. a. Coronal sections through the palate of E15.5 wild-type (WT) and homozygote (Jf/
Jf) embryos, immunohistochemically stained with antibodies against Fbox11, TGF-b3, TGFbR-I, Smad2, and Smad4. Scale bar 50 
mm. Medial edge epithelium (mee), nasal palatal epithelium (ne) and oral palatal epithelium (oe). Graph: comparison of the per-
centage of epithelial cells positive for Smad2 in E15.5 wild-type and homozygote palates. b. Coronal sections through the palate 
of E14.5 (before fusion) and E15.5 (after fusion) wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically 
stained with pSmad2 antibody. Scale bar 50 mm. Medial edge epithelium (mee). Graph: comparison of the percentage of epi-
thelial cells positive for nuclear and cytoplasmic localization of pSmad2 in E15.5 wild-type and homozygote palates. c. Coronal 
sections through the palate of E15.5 wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochemically stained with anti-
bodies against Ki67 and cleaved caspase-3. Scale bar 50 mm. Graph: comparison of the percentage of epithelial cells positive 
for cleaved caspase-3 in E15.5 wild-type and homozygote palates. P-values were determined using two-tailed T-test.
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wild type. Moreover, pSmad2 was present as a nuclear
stain in the majority of the cells of the epidermis. In
homozygote mice 66% of epithelial cells in the upper eye-
lids and 56% of epithelial cells in the lower eyelids
showed nuclear localization of pSmad2, compared with
11% and 17% in the wild-type mice (P = 0.000333, P =
0.0000473) (Figure 4b). Staining was also observed in the
basal layer and also in some cells from the dermis of Jf/Jf
eyelids (Figure 4b). The expression pattern of TGF-b3,
TGFbR-I, TGFbR-II, Smad2, Smad3, Smad4, Smurf2 and
Fbox11 at the same stage E16 in both wild-type and Jf/Jf
eyelids was similar (Figure 4a and Additional file 1). They
were all localized to the cytoplasm of the epithelial cells
of the epidermis (Figure 4a and Additional file 1). We
examined also the distribution of pSmad2 at E15.5,
before the closure. In both wild-type and Jf/Jf eyelids acti-
vated Smad2 was detectable as nuclear and cytoplasmic
staining. In homozygote mice 27% of epithelial cells in
the upper eyelids and 19% of epithelial cells in the lower
eyelids showed nuclear localization of pSmad2, com-
pared with 41% and 32% in the wild-type mice. Eleven
per cent of epithelial cells in the homozygote upper eye-
lids and 9% of epithelial cells in the homozygote lower
eyelids showed cytoplasmic localization of pSmad2, com-
pared with 12% and 9% in the wild-type eyelids (data not
shown) (Figure 4b).
To compare apoptotic cells in wild-type and Jf/Jf junc-
tional zones of the eyelids we again employed cleaved cas-
pase-3 antibody. As with our palate studies, we observed
fewer cells positive for cleaved caspase-3 in Jf/Jf E16 eye-
lids (Figure 4c) (P  = 0.008006 for the upper and P  =
0.0008781 for the lower eyelids). The process of eyelid
closure coordinates both cell proliferation and migration.
We used Ki67 as a marker for proliferation, comparing the
number of Ki67 positive cells in the epidermis of E16 of
wild-type and Jf/Jf eyelids. We saw no significant differ-
ences, indicating that proliferation is not affected in the Jf/
Jf eyelids (Figure 4c).
Lung phenotype of Jf/Jf mice
Newborn Jf/Jf mice die soon after birth and gasp for air.
Moreover, lung development, like palate and eyelid devel-
opment, involves growth of epithelial tissue and, in addi-
tion, the TGF-b signalling pathway is known to be
important in this process. We therefore investigated
whether lung development was affected in Jf/Jf embryos.
Examination of pSmad2 expression in Jf/Jf lungs revealed
a similar picture to that which we had previously observed
in both the eyelids and the palate (Figure 5a). The locali-
zation of pSmad2 in E15.5 wild-type lungs was cytoplas-
mic and nuclear. In Jf/Jf lungs the number of positive cells
was significantly increased and the localization was exclu-
sively nuclear. The increase in pSmad2-positive cells was
particularly striking in proximal airways where 19% of
wild-type proximal airway cells were positive for nuclear
pSmad2, and this increased to 79% in Jf/Jf (P = 0.00005);
see Figure 5a. In contrast, no significant difference was
seen in the localization of Smad2 between wild-type and
Jf/Jf mice. The accumulation of pSmad2 in the nucleus of
whole lungs was also examined by Western blot analysis
(Figure 5b) and clearly demonstrated a marked increase in
Eyelid open phenotype Figure 3
Eyelid open phenotype. a. Haematoxylin-eosin stained coronal sections through the eyes of E15.5 (before fusion) and E16 
(after fusion) in wild-type (WT) and homozygote (Jf/Jf) embryos. Scale bars 200 mm. b. Failure of eyelids closure in a homozy-
gote mouse (Jf/Jf) at birth (arrow).
b.
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nuclear localization in Jf/Jf homozygotes, consistent with
our observations from immunostaining. Immunostaining
of lungs with a marker for proliferation (Ki67) showed no
difference between wild-type and homozygous mutant
lungs (Figure 5a).
In newborn Jf/Jf mice the lungs are severely affected. We
observed thickened interstitial mesenchyme and fewer,
smaller alveoli than in wild-type littermates. On average,
the airway width in homozygous mutants was signifi-
cantly smaller than wild-type tissue (Figure 5c). Moreover,
quantification of the number of airways indicated a very
significant reduction in homozygous mutants (Figure 5c).
The mutant mice die soon after birth, probably as a con-
sequence of their lung defect. Cleft palate does not lead to
death this early. Immunostaining of lungs with a marker
for Clara cells in the proximal airways (CC10) showed no
difference in the number or structure of proximal airways
between wild-type and homozygous mutant lungs (data
not shown).
Immunolocalization in eyelid tissue Figure 4
Immunolocalization in eyelid tissue. a. Coronal sections through the eye of E16 wild-type (WT) and homozygote (Jf/Jf) 
embryos immunohistochemically stained with antibodies against Fbox11, TGF-b3, TGFbR-I, Smad3, Smad2 and Smad4. Scale 
bar 200 mm. Graph: comparison of the percentage of epithelial cells positive for Smad2 in E16 upper and lower eyelids. b. 
Coronal sections through the eyes of E15.5 (before fusion) and E16 (after fusion) in wild-type (WT) and homozygote (Jf/Jf) 
embryos stained with pSmad2 antibody (scale bar 200 mm). Epidermis (ep), basal cells (bc) and dermis (d). Graph: comparison 
of the percentage of epithelial cells with positive nuclear and cytoplasmic localization of pSmad2 in E16 upper and lower eye-
lids. c. Coronal sections through the eyes of E16 in wild-type (WT) and homozygote (Jf/Jf) embryos stained with Ki67 and 
cleaved caspase-3 antibodies. Scale bar 200 mm. Graph: comparison of the percentage of epithelial cell positive for Ki67 and 
cleaved caspase-3 in E16 upper and lower eyelids. P-values were determined using two-tailed T-test comparing each homozy-
gote eyelid with the wild type.
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Genetic interaction of Fbxo11 and Smad2
It appears that the Jeff mutation results in an increased
expression as well as increased nuclear localization of
pSmad2 in epithelial tissues. We therefore decided to
examine genetically the interaction of Smad2 and Fbox11.
We crossed mice heterozygous for a Smad2 null mutation
to  Jeff  heterozygotes to produce double heterozygous
mice:  Jf/+ Smad2/+. Double heterozygotes comprised
21.6% (57/264) of mice from this cross, significantly dif-
ferent from expected (c2 = 8.54546, P = 0.035986, df = 3).
However, 66% (36/57) of Jf/+ Smad2/+ mice died soon
after birth due to respiratory problems. We performed an
extensive histological examination of the palates and
lungs of Jf/+ Smad2/+, Jf/+, Smad2/+ and wild-type mice.
Notably, Jf/+ Smad2/+ mice with early postnatal mortality
demonstrated cleft palate and poorly developed lungs,
recapitulating the Jf/Jf phenotype of smaller and fewer air-
ways (Figure 6). A proportion (34%) of Jf/+ Smad2/+ mice
survives. These mice do not have cleft palate and appear
to display a milder lung phenotype (Figure 6). The surviv-
ing double heterozygous mice are also smaller than their
wild-type and single heterozygous littermates.
Lung phenotype Figure 5
Lung phenotype. a. Sections through the lungs of E15.5 wild-type (WT) and homozygote (Jf/Jf) embryos, immunohistochem-
ically stained with antibodies against Ki67, Smad2 and pSmad2 (scale bars 200 mm and 20 mm as indicated). Graphs: compari-
son of the percentage of cells positive for Ki67, Smad2 and pSmad2 in proximal airways. b. Western blot analysis: cytoplasmic 
and nuclear fractions from wild-type (wt), heterozygote (Jf/+) and homozygote (Jf/Jf) whole E15.5 lungs. Equal amounts of pro-
tein were subjected to tris-acetate PAGE, transferred and probed with pSmad2 and actin antibody for loading control. Graph: 
comparison of the normalised pSmad2 signals in the two fractions. c. Haematoxylin-eosin stained sections through new born 
wild-type (WT) and homozygote (Jf/Jf) lungs. Scale bars 200 mm. Graph: comparison of the number of airways for three 
regions of 5.3 × 106 mm2 taken at random and the width of 3 × 30 airways for each genotype. P-values were determined using 
two-tailed T-test.
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Genetic interaction of Fbxo11 and p53
Recently, it has been shown that Fbxo11 acts as a Nedd8-
ligase to p53. Neddylation of p53 by Fbxo11 leads to a
reduction in transcriptional activity [14]. Given these
findings and that p53 is a co-factor of pSmad2, we exam-
ined the genetic interaction between p53 and Fbxo11. Jf/+
mice and p53 homozygotes were intercrossed to produce
double heterozygotes – Jf/+ p53/+. Compound heterozy-
gotes comprised 44.9% (31/69) of the mice born from
this cross (c2 = 0.72464, P = 0.399397, df = 1). However,
all Jf/+ p53/+ mice appeared phenotypically normal (data
not shown).
Biochemical interactions of Fbxo11, Smad2 and p53
We explored further the genetic interaction between
Fbxo11 and Smad2 by performing immunoprecipitations
to test whether these two proteins interact. We used a
cross-linking agent to improve the likelihood of detecting
the interactions. However, immunoprecipitations with
Smad2 antibodies failed to reveal any interaction with
Fbxo11 (Figure 7a), suggesting that Smad2 or pSmad2 is
not a substrate for ubiquitination by Fbxo11. However,
Smad2 did immunoprecipitate p53, confirming the
known interaction between these two proteins (Figure
7a).
We also undertook immunoprecipitations with p53 (Fig-
ure 7a) using lung tissue. We also failed to detect any
interaction between Fbxo11 and p53, despite the reported
neddylation of p53 by Fbxo11. Intriguingly, we find that
in Jeff homozygote mice p53 is expressed at very low levels
(Figure 7b and 7c). The heterozygote appears to display
intermediate levels. These results suggest that Fbxo11
plays a role in stabilising p53.
Lung phenotype of double heterozygotes Figure 6
Lung phenotype of double heterozygotes. a. Sections through the lungs of newborn wild-type (+/+ +/+), heterozygote 
for Smad2 (+/+ Smad2/+), heterozygote for Jeff (Jf/+ +/+) and two double heterozygote (Smad2/+ Jf/+) mice: with and without 
cleft palate. The sections were haematoxylin-eosin stained. Scale bars 200 mm. b. Graphic comparison of the number of airways 
for three regions of 5.3 × 106 mm2 taken at random and the width of airways for each genotype. P-values were determined using 
two-tailed T-test comparing each with the wild type.
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Discussion
We previously identified a mutation in Fbxo11 in the Jeff
mutant mice [8]. Jeff heterozygote mice develop chronic
OM [7] and Jeff  homozygotes demonstrate perinatal
lethality, cleft palate and an EOB phenotype [8]. We inves-
tigated the impact of the Jeff mutation on the TGF-b sig-
nalling pathway, paying particular attention to those
members of the pathway that have a role in epithelial
development.
In mammalian development the formation of the palate
is a multi-step process, involving palatal shelf growth and
elevation above the tongue, followed by fusion of the
shelves and the disappearance of the MEE [31]. Defects in
any of these steps can lead to cleft palate, one of the most
common birth defects in humans. Murine palatogenesis
takes place between E11.5 and E15.5 [31]. All TGF-b lig-
ands are known to be expressed at that stage in the devel-
oping palate [32]. Amongst them, TGF-b3 is likely to be
the most important in palatogenesis since mutation of the
gene causes cleft palate in mice [29,33] and humans [34].
In palate cultures from these mutant embryos, the fusion
defect is rescued by endogenous TGF-b3 [35]. It has been
demonstrated that TGF-b3 selectively regulates the disap-
pearance of MEE during palatal fusion: TGF-b3 disinte-
grates the MEE basement membrane [36]. Studies on the
mechanism for MEE disappearance during palatal fusion
suggests a role of TGF-b3 as an inducer of apoptosis – cell
death in TGF-b3 null palates is reduced at the time of
fusion [37]. Smad2 and Smad3, mediators of TGF-b sig-
nalling, are expressed in the MEE cells, but only Smad2 is
phosphorylated during palatal fusion. Smad2 phosphor-
ylation is temporo-spatially restricted to the MEE and cor-
relates with the disappearance of the MEE [30]. TGF-b3 is
Immunoprecipitation and Western blot analysis Figure 7
Immunoprecipitation and Western blot analysis. a. Immunoprecipitation: lung extract from E15.5 wild-type embryos 
was used for immunoprecipitation using Smad2 and p53 antibodies. The Western blots were probed with pSmad2, Fbox11 and 
p53 antibodies. b. Western blot analysis: protein lysates from wild-type, heterozygote and homozygote E15.5 palates. Equal 
amounts of protein were subjected to tris-acetate PAGE, transferred and probed with pSmad2, Fbox11, p53 antibodies and 
actin antibody for loading control. c. Graphical representation of p53 levels normalized against actin in wild-type, heterozygote 
and homozygote E15.5 palates, showing approximately threefold reduction of p53 in homozygote palate compared with wild 
type.
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required for phosphorylation of Smad2 in the MEE and
the inhibition of MEE proliferation during palatal fusion
[30].
Our studies using IHC to co-localize the TGF-b3 ligand,
TGF-b receptors and Smads in developing palates revealed
one major difference between wild-type and Jf/Jf mice. At
E15.5 more epithelia cells are positive for pSmad2 in the
homozygote palatal shelves than in the wild type. Moreo-
ver, we found that there was a substantial increase in
nuclear localization of pSmad2 in Jf/Jf mice. This might
suggest that the turnover of pSmad2 is stalled and
pSmad2 accumulates in the nucleus, with consequent
effects for TGF-b signalling in the epithelia.
TGF-b3 plays a role as an inhibitor of MEE proliferation
during palatal fusion [30] and an inducer of apoptosis
[37]. Using Ki67 as a marker for proliferation we did not
observe increased proliferation in E14.5 and E15.5 palates
of the Jeff homozygote MEE. However, we also stained for
apoptotic cells using a caspase-3 antibody and found
many fewer positive cells in Jeff homozygote E15.5 pal-
ates. It appears that in the presence of a mutation in
Fbxo11, palatal fusion is inhibited and MEE cells are not
able to progress to epithelial programmed cell death or
epithelial-mesenchymal transformation.
The palatal shelves fusion is a permanent fusion, such as
the fusion of the neural tube. During mammalian devel-
opment some temporary fusions also occur for example,
eyelid fusion, fusion of the digits and fusion of the pinnae
of the ears to the scalp. The disjunction of the temporary
fusions takes place after birth [38]. The eyelids develop at
approximately the same time as the palatal shelves. They
start to form at about E11.5, grow across the eye from E14
to E16 and, as the fusion progresses, the diminishing gap
fills with a profusion of rounded cells that are extruded,
flattened, and sloughed off from the area of completed
fusion [38,39]. Failure of the eyelids to grow and fuse in
mice leads to the EOB defect. Mouse knockout studies
have identified several signalling molecules involved in
the control of embryonic eyelid closure and some of them
are from the TGF-b family. Mutation in activin bB results
in an EOB phenotype [40] similar to that observed in
MEKK1-deficient mice [41]. TGF-b/activin signalling via
the MEKK1-mediated JNK pathway is one pathway con-
trolling eyelid closure [17,42]. MEKK1 is not required
however for the classical TGF-b/activin pathway, which
involves nuclear translocation of Smad proteins [17].
Normally in mouse development, the eyelid fusion is
complete by E16, but the eyelids of Jeff homozygote mice
remain wide apart. The eyelids start to form the leading
edge of the developing margins, but the leading edge is
not extended and the eyelids do not reach each other. We
applied the same panel of antibodies, employed on the
palates, on sections of E16 eyelids. The expression pattern
of TGF-b3 and the signalling receptor TGFbR-I are consist-
ent with localization observed in the cytoplasm of the
cells of the epidermis of both the developing wild-type
and mutant eyelids. The distribution of non-activated
Smads is also similar, but with pSmad2 there is a clear dif-
ference between the wild-type and homozygote eyelids.
Activated Smad2 was present as a nuclear stain in the
majority of the cells of the epidermis, the basal layer and
also some cells from the dermis of the Jeff homozygote
eyelids. In contrast, in wild-type eyelids the pSmad2 is
localized in the cytoplasm of the epidermis. The differ-
ence is also time specific. At E15.5 before eyelid fusion the
pattern and the localization of activated Smad2 is similar
in wild type and Jf/Jf. These findings mirror and are con-
sistent with the expression changes observed in the palate.
In the developing eyelid, as with the palate, we also stud-
ied proliferation and apoptosis in the Jeff homozygote.
Using Ki67 as a marker for proliferation, we found that
there was little difference between wild-type and mutant
homozygotes in the number or distribution of cells
stained. However, we found significantly lower staining
with caspase-3 in the Jeff homozygote, indicating reduced
rates of apoptosis. It would appear that, as with the palate,
the absence of epithelial fusion prevents the transition to
epithelial programmed cell death.
We show here that, in addition to palatal and eyelid devel-
opment defects, the development of the lung in Jeff
homozygotes is severely compromised. In the mouse,
early lung development begins at about E9.5 with the for-
mation of the paired lung buds and continues through the
pseudoglandular phase at E9.5-16.5 when the bronchial
and respiratory tree develops, and the canalicular phase
E16.5-17.5 when vascularization occurs. During late lung
development at E17.5-P4 the distal airways form saccular
units (saccular stage) and the secondary septae divides
these units during the alveolar stage at P5-28 [43,44].
Several studies have implicated TGF-b signalling in early
lung development. Immunohistochemical studies on
localization of the three TGF-b isoforms in the developing
mouse embryo suggest that they play an important role in
lung formation [18]. TGF-b signalling is implicated in the
negative regulation of lung growth and development dur-
ing early lung organogenesis [45]. Recent expression data
also indicates that active TGF-b signalling is required for
normal late lung development [46]. Gene-targeting stud-
ies also demonstrate the involvement of the TGF-b family
in early and late lung morphogenesis. TGF-b3 null new-
born mice have under-developed and poorly inflated
lungs [33]. The developmental delay is detectable as early
as day E12.5, which implicates a role of TGF-b3 in early
lung development. Retarded lung alveolarization and
subsequent emphysema in Smad3 knockout mice, on thePathoGenetics 2009, 2:5 http://www.pathogeneticsjournal.com/content/2/1/5
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other hand, suggests a role for the TGF-b/Smad3 pathway
in postnatal lung growth and emphysema prevention
[47]. As the TGF-b family is involved in lung morphogen-
esis and reflecting the changes in pSmad2 expression and
localization in the palate and eyelid, we have explored
pSmad2 in the developing lung. Again, we find a signifi-
cant increase in the expression of pSmad2. Most notably,
there is a very marked increase in localization of pSmad2
to the nuclei of epithelial cells lining the airways.
Given the effects of the Fbxo11 mutation on pSmad2 in a
variety of tissues, we decided to examine genetically the
interaction between these two genes and generated Jf/+
Smad2/+  compound heterozygotes. Intriguingly, we
found that Jf/+ Smad2/+ mice recapitulated many of the
features of Jeff homozygotes, including the cleft palate,
lung phenotype and post-natal mortality. The phenotypes
of the Jf/+ Smad2/+ compound heterozygote are not fully
penetrant. Around one-third of Jf/+ Smad2/+ mice survive
but are much smaller than wild-type or single-mutant lit-
termates. The developmental abnormalities observed in
the Jf/+ Smad2/+ mice contrasts with the normal pheno-
type seen in Jf/+ mice and underlines the effects of the
Fbxo11 mutation on pSmad2. It would appear that a com-
plete absence of Fbxo11 function, with consequent effects
on pSmad2 expression and localization, can lead to the
epithelial developmental defects that we have observed.
Alternatively, compromising levels of gene expression at
both the Fbxo11 and Smad2 loci leads to the same pheno-
type.
Despite the effects of the Fbxo11 mutation, and the genetic
interaction observed between Fbxo11 and Smad2, we
failed to observe any biochemical interaction between
Fbxo11 and Smad2. As expected we were able to demon-
strate the known interaction between Smad2 and p53. It
has been reported that Fbxo11 neddylates p53, inhibiting
its transcriptional activity [14]. However, immunoprecip-
itations did not reveal an interaction in the tissues we
tested. Indeed, Jf/+ p53/+ compound heterozygotes did
not show any developmental phenotypes. Nevertheless,
we found that Jeff homozygotes have markedly reduced
levels of p53 and heterozygotes appeared to have interme-
diate levels. It appears that Fbxo11 is required for stabili-
sation of p53.
p53 is required for TGF-b responses through its interac-
tions with Smads [15]. p53-deficient mammalian cells
demonstrate impaired responses to TGF-b signals. Most
importantly, p53 and Smad2 cooperated synergistically at
target promoters for TGF-b signalling, and indeed they
directly interact in vivo in a TGF-b-dependent fashion [15].
We propose that in the Jeff homozygous mutant, loss of
Fbxo11  function leads to destabilisation of p53 by an
unknown mechanism. It is possible, given the synergistic
interaction between p53 and Smad2, that the loss of p53
at transcriptional targets leads to stalling and accumula-
tion of pSmad2 in the nuclei of epithelial tissues of Jeff
homozygotes. Mutant p53 leads to attenuation of TGF-b1
signalling including a reduction in Smad2/3 phosphor-
ylation, inhibition of Smad2/Smad4 complex formation
and Smad4 translocation to the nucleus [48]. Overall,
given the interaction between p53 and TGF-b signalling
pathways, it seems likely that the effects of the Fbxo11
mutation on TGF-b signalling may be mediated through
effects on p53.
Chronic and recurrent OM in the human population is
known to have a very significant genetic component, yet
little is known about the underlying genes or pathways
involved. Moreover, although a number of mouse strains
are available that show OM, they are complicated by poor
penetrance or the complex syndromic nature of the dis-
ease. Jeff heterozygotes develop a highly penetrant chronic
suppurative OM in the absence of any other significant
pathology [7,8] and thus the Jeff mutant represents a pow-
erful model for studying the genetic and pathophysiolog-
ical bases of chronic/recurrent OM. The discovery of the
Fbxo11  gene underlying the Jeff mutant identified an
important candidate for the study of OM in the human
population. Indeed, initial studies with FBXO11 SNPs in
human OM families have demonstrated nominal evi-
dence of association, indicating the genetic involvement
of human FBXO11 with chronic and recurrent OM [49].
Conclusion
The studies reported here support a role for Fbxo11 in
TGF-b signalling and suggest that perturbations in this
pathway may underlie chronic inflammation in the mid-
dle ear. This is particularly pertinent given the studies of a
similar mouse mutant with chronic OM, Junbo [9], caused
by a mutation in the transcription factor Evi1 which is a
co-repressor of Smad3. Overall, there is increasing evi-
dence that defects in TGF-b signalling or associated path-
ways may underlie the development of chronic OM, and
genes in these pathways represent good candidates for
future human association studies.
Methods
Mice
The Jeff, Smad2 and p53 colonies were maintained on the
C57BL/6J background and genotyped as previously
described [8,50,51].
Histology
The embryonic (E14.5-E16) and newborn heads and bod-
ies were fixed in 10% buffered formaldehyde, decalcified
and embedded in paraffin following routine procedures.
The lungs of the newborn mice were inflated with 10%
buffered formaldehyde, fixed and paraffin-embedded.PathoGenetics 2009, 2:5 http://www.pathogeneticsjournal.com/content/2/1/5
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Three-micrometer-thick sections were obtained, de-par-
affinized in xylene substitute and rehydrated via a graded
ethanol. For morphological observations, sections were
stained with haematoxylin and eosin.
Antibodies
The antibodies were as follows: rabbit polyclonal TGF-b3
(sc-90, Santa Cruz Biotechnology), rabbit polyclonal
TGFbR-I (sc-398, Santa Cruz Biotechnology), rabbit poly-
clonal TGFbR-II (ab28382, Abcam), goat polyclonal
Smad2 (sc-6200 Santa Cruz Biotechnology), rabbit poly-
clonal Smad3 (06-920 Upstate), rabbit polyclonal Smad4
(06-693 Upstate), rabbit polyclonal anti-phospho Smad2
(Ser 465/467) (AB3849 Chemicon International and
3101 Cell Signaling), rabbit polyclonal SMURF2 (07-249
Upstate), rabbit polyclonal FBXO11 (A301-177A, A301-
178A Bethyl Laboratories), rabbit polyclonal Fbxo11 pro-
duced by Covalab UK [8], rabbit polyclonal p53 (sc-6243
Santa Cruz Biotechnology), agarose-conjugated mouse
monoclonal p53 (sc-126 AC), rabbit polyclonal Ki67 (VP-
K451 Vector Laboratories), rabbit polyclonal cleaved cas-
pase-3 antibody (9661 Cell Signaling Technology).
Immunostaining
For immunohistochemical analysis, the avidin-biotin
complex (ABC) method was used for all the antibody
stainings except for the TGF-b3 antibody. Endogenous
peroxidase activity was quenched with 3% hydrogen per-
oxide in isopropanol for 20 min. Slides for Ki67, cleaved
caspase-3, TGFb-RII and SMURF2 antibodies were pre-
treated by boiling in a microwave in 10 mM sodium cit-
rate buffer pH 6 for 14 min. Slides for Fbxo11 were pre-
treated by boiling in a microwave in water for 14 min.
After pre-treatment the slides were cooled at room tem-
perature for 20 min and rinsed with phosphate-buffered
saline. To inhibit non-specific endogenous biotin stain-
ing, the DAKO Biotin Blocking System was used (DAKO,
X0590). Rabbit ABC Staining system (sc-2018 Santa Cruz
Biotechnology) and goat ABC staining system (sc-2023
Santa Cruz Biotechnology) were used to develop the spe-
cific signals with all the antibodies except for TGF-b3. The
antibody incubations were as follow: TGFb-RII 1:100
dilution and SMURF2 1:200 dilution for 30 min; Fbxo11
1:200 dilution for 1 h, TGFb-RI, Smad2, pSmad2 (Ser
465/467), Smad3 and Smad4 overnight using a 1:200
dilution; Ki67 was incubated for 1 h at room temperate
using a 1:1000 dilution, and cleaved caspase-3 for 1 h in
1:200 dilution. The slides were counterstained with hae-
matoxylin.
For the immunohistochemical analysis with TGF-b3 anti-
body, slides were blocked with 5% bovine serum albu-
min, incubated with the antibody overnight using a 1:200
dilution, washed with phosphate-buffered saline, and an
anti-rabbit FITC-conjugated antibody (Sigma, F7512) was
used as a secondary antibody for 30 min at room temper-
ature in 1:160 dilution. Sections were washed with phos-
phate-buffered saline, mounted in Vectashield mounting
medium (Vector Laboratories) and the staining was
observed by fluorescence microscopy. Negative control
sections were incubated with serum instead of the anti-
body and otherwise processed identically.
Immunoprecipitation
Protein samples from lungs of E15.5 wild-type embryos
were prepared by homogenizing in phosphate buffer solu-
tion, containing 1% triton X100, 0.5% deoxycholic acid
and cocktail of protease inhibitors. The samples were
incubated with 2 mM 3,3'-Dithiobis [sulfosuccinimidyl-
propionate] (DTSSP) cross-linker for 30 min at room tem-
perature and treated as described by the manufacturer
(PIERCE, 21578). Total protein extract of 1 mg was pre-
cleared with 15 ml Sepharose-protein G beads (Sigma) for
1 h at 4°C with rotation. The pre-cleared extract was incu-
bated with 4 mg of antibody (Smad 2, p53) overnight at
4°C. Twenty microlitres of protein G beads was added
and allowed to bind for 3 h at 4°C with rotation. Beads
were washed four times with 500 ml of extraction buffer
and resuspended in electrophoresis loading buffer/reduc-
ing agent (NuPAGE, Invitrogen). As a negative control, an
identical reaction was prepared where goat IgG (for
Smad2) or mouse IgG (for p53) was used instead of the
specific antibody. Cross-linking reversal was achieved by
incubation at 37°C for 30 min, after which samples were
heated at 70°C for 10 min and resolved in NuPAGE 7%
Tris-Acetate gels (Invitrogen). Only one third of the total
reaction was loaded per lane.
Nuclear and cytoplasmic fractionation
For the fractionation CelLytic NuCLEAR Extraction kit
(Sigma, NXTRACT) was used. E15.5 lungs were lysed in
1× lysis buffer containing protease and phosphatase
inhibitors using a glass homogenizer. Nuclei were pel-
leted by centrifugation and the cytoplasmic fraction
obtained by retaining the supernatant. The nuclear
extracts were obtained by resuspending the nuclei pellet
in extraction buffer containing protease and phosphatase
inhibitors, rocking the pellet for 30 min and subsequent
centrifugation. Twenty micrograms of each protein sam-
ple was loaded on each lane.
Western blot
Gels were blotted onto PVDF (GE Healthcare) and
blocked in phosphate-buffered saline containing 5% dry
skimmed milk and 0.1% Tween 20. Antibodies were
diluted in blocking solution at 1:250 (anti-p53), 1:500
(anti-pSmad2), 1:500 (anti-FBOX11) or 1:10,000 (anti-
rabbit-HRP). Incubation with primary antibodies pro-
ceeded overnight at 4°C and with secondary antibody for
1 h at room temperature. Membranes were washed fourPathoGenetics 2009, 2:5 http://www.pathogeneticsjournal.com/content/2/1/5
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times between antibodies and after secondary antibody in
phosphate-buffered saline and 0.1% Tween 20. ECL Plus
(GE Healthcare) was used as detection system.
Data analysis
We used chi-squared test to compare the difference
between the observed and the expected number of the
double heterozygous mice from the two crosses. To evalu-
ate the probability of the calculated chi-squared value the
chidist function in Excel was used.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HT carried out the immunostaining analysis, some of the
proteomics analysis, contributed to the design of the
study and the interpretation of the results and participated
in drafting the manuscript. RH contributed to the analysis
and discussion of the results. SM participated in the phe-
notyping and the genotyping of some of the mice, and
MRR and HH performed most of the immunoprecipita-
tions and western blot analysis and contributed to the
interpretation of the results from these studies. CD helped
with the study of the lung phenotype of the mice and con-
tributed to the interpretations of the results. SDMB con-
tributed to the design of the study, interpretation of
results and participated in drafting the manuscript. All
authors read and approved the final manuscript.
Additional material
Acknowledgements
This work was funded by the MRC. The authors would like to thank Caro-
line Barker, Jennifer Corrigan, Adele Seymour, Elizabeth Darley and Terry 
Hacker for histology services, David Shipston and Jim Humphreys for 
necropsy skills and Tim Randall, Lucie Vizor and Sara Wells for technical 
support. The authors are also grateful to Liz Robertson for the Smad2 
knockout mice and to Lawrence Donehower for the p53 knockout mice.
References
1. Kubba H, Pearson JP, Birchall JP: The aetiology of otitis media
with effusion: a review.  Clin Otolaryngol Allied Sci 2000, 25:181-194.
2. Davidson J, Hyde ML, Alberti PW: Epidemiologic patterns in
childhood hearing loss: a review.  Int J Pediatr Otorhinolaryngol
1989, 17:239-266.
3. Daly KA, Brown WM, Segade F, Bowden DW, Keats BJ, Lindgren BR,
Levine SC, Rich SS: Chronic and recurrent otitis media: a
genome scan for susceptibility loci.  Am J Hum Genet 2004,
75:988-997.
4. Casselbrant ML, Mandel EM, Fall PA, Rockette HE, Kurs-Lasky M,
Bluestone CD, Ferrell RE: The heritability of otitis media: a twin
and triplet study.  JAMA 1999, 282:2125-2130.
5. Casselbrant ML, Mandel EM, Rockette HE, Kurs-Lasky M, Fall PA,
Bluestone CD, Ferrell RE: The genetic component of middle ear
disease in the first 5 years of life.  Arch Otolaryngol Head Neck Surg
2004, 130:273-278.
6. Nolan PM, Peters J, Strivens M, Rogers D, Hagan J, Spurr N, Gray IC,
Vizor L, Brooker D, Whitehill E, Washbourne R, Hough T, Greena-
way S, Hewitt M, Liu X, McCormack S, Pickford K, Selley R, Wells C,
Tymowska-Lalanne Z, Roby P, Glenister P, Thornton C, Thaung C,
Stevenson JA, Arkell R, Mburu P, Hardisty R, Kiernan A, Erven A, et
al.: A systematic, genome-wide, phenotype-driven mutagen-
esis programme for gene function studies in the mouse.  Nat
Genet 2000, 25:440-443.
7. Hardisty RE, Erven A, Logan K, Morse S, Guionaud S, Sancho-Oliver
S, Hunter AJ, Brown SD, Steel KP: The deaf mouse mutant Jeff
(Jf) is a single gene model of otitis media.  J Assoc Res Otolaryngol
2003, 4:130-138.
8. Hardisty-Hughes RE, Tateossian H, Morse SA, Romero MR, Middle-
ton A, Tymowska-Lalanne Z, Hunter AJ, Cheeseman M, Brown SD: A
mutation in the F-box gene, Fbxo11, causes otitis media in
the Jeff mouse.  Hum Mol Genet 2006, 15:3273-3279.
9. Parkinson N, Hardisty-Hughes RE, Tateossian H, Tsai HT, Brooker D,
Morse S, Lalane Z, MacKenzie F, Fray M, Glenister P, Woodward AM,
Polley S, Barbaric I, Dear N, Hough TA, Hunter AJ, Cheeseman MT,
Brown SD: Mutation at the Evi1 locus in Junbo mice causes
susceptibility to otitis media.  PLoS Genet 2006, 2:e149.
10. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW: Sys-
tematic analysis and nomenclature of mammalian F-box
proteins.  Genes Dev 2004, 18:2573-2580.
11. Kipreos ET, Pagano M: The F-box protein family.  Genome Biol
2000, 1:REVIEWS3002.
12. Fielenbach N, Guardavaccaro D, Neubert K, Chan T, Li D, Feng Q,
Hutter H, Pagano M, Antebi A: DRE-1: an evolutionarily con-
served F box protein that regulates C. elegans developmen-
tal age.  Dev Cell 2007, 12:443-455.
13. Cook JR, Lee JH, Yang ZH, Krause CD, Herth N, Hoffmann R, Pestka
S:  FBXO11/PRMT9, a new protein arginine methyltrans-
ferase, symmetrically dimethylates arginine residues.  Bio-
chemical Biophys Res Commun 2006, 342:472-481.
14. Abida WM, Nikolaev A, Zhao W, Zhang W, Gu W: FBXO11 pro-
motes the Neddylation of p53 and inhibits its transcriptional
activity.  J Biol Chem 2007, 282:1797-1804.
15. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo
S:  Links between tumor suppressors: p53 is required for
TGF-beta gene responses by cooperating with Smads.  Cell
2003, 113:301-314.
16. Prime SS, Pring M, Davies M, Paterson IC: TGF-beta signal trans-
duction in oro-facial health and non-malignant disease (part
I).  Crit Rev Oral Biol Med 2004, 15:324-336.
17. Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, Gao M, Liu CY, Kao
WW, Karin M, Xia Y: A role for MEK kinase 1 in TGF-beta/
activin-induced epithelium movement and embryonic eyelid
closure.  EMBO J 2003, 22:4443-4454.
18. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI: Immunohisto-
chemical localization of TGF beta 1, TGF beta 2, and TGF
beta 3 in the mouse embryo: expression patterns suggest
multiple roles during embryonic development.  J Cell Biol 1991,
115:1091-1105.
19. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell
membrane to the nucleus.  Cell 2003, 113:685-700.
20. Massague J, Chen YG: Controlling TGF-beta signaling.  Genes Dev
2000, 14:627-644.
21. Izzi L, Attisano L: Ubiquitin-dependent regulation of TGFbeta
signaling in cancer.  Neoplasia 2006, 8:677-688.
22. Izzi L, Attisano L: Regulation of the TGFbeta signalling path-
way by ubiquitin-mediated degradation.  Oncogene 2004,
23:2071-2078.
23. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH: A SMAD
ubiquitin ligase targets the BMP pathway and affects embry-
onic pattern formation.  Nature 1999, 400:687-693.
Additional file 1
Immunolocalization of TGFbR-II and Smurf2. Sections through E15.5 
palate, E16 eyelids and E15.5 lungs of wild-type (WT) and homozygote 
(Jf/Jf) embryos, immunohistochemically stained with antibodies against 
TGFbR-II (upper panel) and Smurf2 (lower panel). Scale bars 20, 50 
and 200 mm as indicated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8417-2-5-S1.ppt]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
PathoGenetics 2009, 2:5 http://www.pathogeneticsjournal.com/content/2/1/5
Page 14 of 14
(page number not for citation purposes)
24. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R:
Regulation of Smad degradation and activity by Smurf2, an
E3 ubiquitin ligase.  Proc Natl Acad Sci USA 2001, 98:974-979.
25. Lin X, Liang M, Feng XH: Smurf2 is a ubiquitin E3 ligase mediat-
ing proteasome-dependent degradation of Smad2 in t rans-
forming growth factor-beta signaling.  Journal Biol Chem 2000,
275:36818-36822.
26. Fukuchi M, Imamura T, Chiba T, Ebisawa T, Kawabata M, Tanaka K,
Miyazono K: Ligand-dependent degradation of Smad3 by a
ubiquitin ligase complex of ROC1 and associated proteins.
Mol Biol Cell 2001, 12:1431-1443.
27. Aoyama Y, Urushiyama S, Yamada M, Kato C, Ide H, Higuchi S, Aki-
yama T, Shibuya H: MFB-1, an F-box-type ubiquitin ligase, reg-
ulates TGF-beta signalling.  Genes Cells 2004, 9:1093-1101.
28. Mavrakis KJ, Andrew RL, Lee KL, Petropoulou C, Dixon JE, Navarat-
nam N, Norris DP, Episkopou V: Arkadia enhances Nodal/TGF-
beta signaling by coupling phospho-Smad2/3 activity and
turnover.  PLoS Biol 2007, 5:e67.
29. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN,
Ding J, Ferguson MW, Doetschman T: Transforming growth fac-
tor-beta 3 is required for secondary palate fusion.  Nat Genet
1995, 11:409-414.
30. Cui XM, Chai Y, Chen J, Yamamoto T, Ito Y, Bringas P, Shuler CF:
TGF-beta3-dependent SMAD2 phosphorylation and inhibi-
tion of MEE proliferation during palatal fusion.  Dev Dyn 2003,
227:387-394.
31. Ferguson MW: Palate development.  Dev Suppl 1988, 103:41-60.
32. Fitzpatrick DR, Denhez F, Kondaiah P, Akhurst RJ: Differential
expression of TGF beta isoforms in murine palatogenesis.
Development 1990, 109:585-595.
33. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D,
Heisterkamp N, Groffen J: Abnormal lung development and
cleft palate in mice lacking TGF-beta 3 indicates defects of
epithelial-mesenchymal interaction.  Nat Genet 1995,
11:415-421.
34. Lidral AC, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-
Hirsch S, Semina EV, Johnson LR, Machida J, Burds A, Parnell TJ,
Rubenstein JL, Murray JC: Association of MSX1 and TGFB3 with
nonsyndromic clefting in humans.  Am J Hum Genet 1998,
63:557-568.
35. Taya Y, O'Kane S, Ferguson MW: Pathogenesis of cleft palate in
TGF-beta3 knockout mice.  Development 1999, 126:3869-3879.
36. Kaartinen V, Cui XM, Heisterkamp N, Groffen J, Shuler CF: Trans-
forming growth factor-beta3 regulates transdifferentiation
of medial edge epithelium during palatal fusion and associ-
ated degradation of the basement membrane.  Dev Dyn 1997,
209:255-260.
37. Martinez-Alvarez C, Tudela C, Perez-Miguelsanz J, O'Kane S, Puerta
J, Ferguson MW: Medial edge epithelial cell fate during palatal
fusion.  Dev Biol 2000, 220:343-357.
38. Harris MJ, McLeod MJ: Eyelid growth and fusion in fetal mice. A
scanning electron microscope study.  Anat Embryol 1982,
164:207-220.
39. Findlater GS, McDougall RD, Kaufman MH: Eyelid development,
fusion and subsequent reopening in the mouse.  J Anat 1993,
183:121-129.
40. Vassalli A, Matzuk MM, Gardner HA, Lee KF, Jaenisch R: Activin/
inhibin beta B subunit gene disruption leads to defects in
eyelid development and female reproduction.  Genes Dev 1994,
8:414-427.
41. Yujiri T, Ware M, Widmann C, Oyer R, Russell D, Chan E, Zaitsu Y,
Clarke P, Tyler K, Oka Y, Fanger GR, Henson P, Johnson GL: MEK
kinase 1 gene disruption alters cell migration and c-Jun NH2-
terminal kinase regulation but does not cause a measurable
defect in NF-kappa B activation.  Proc Natl Acad Sci USA 2000,
97:7272-7277.
42. Xia Y, Karin M: The control of cell motility and epithelial mor-
phogenesis by Jun kinases.  Trends Cell Biol 2004, 14:94-101.
43. Ten Have-Opbroek AA: Lung development in the mouse
embryo.  Exp Lung Res 1991, 17:111-130.
44. Copland I, Post M: Lung development and fetal lung growth.
Paediatr Respir Rev 2004, 5(Suppl A):S259-264.
45. Maeda Y, Dave V, Whitsett JA: Transcriptional control of lung
morphogenesis.  Physiol Rev 2007, 87:219-244.
46. Alejandre-Alcazar MA, Michiels-Corsten M, Vicencio AG, Reiss I, Ryu
J, de Krijger RR, Haddad GG, Tibboel D, Seeger W, Eickelberg O,
Morty RE: TGF-beta signaling is dynamically regulated during
the alveolarization of rodent and human lungs.  Dev Dyn 2008,
237:259-269.
47. Chen H, Sun J, Buckley S, Chen C, Warburton D, Wang XF, Shi W:
Abnormal mouse lung alveolarization caused by Smad3 defi-
ciency is a developmental antecedent of centrilobular
emphysema.  Am J Physiol Lung Cell Mol Physiol 2005, 288:L683-691.
48. Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L,
Stambolsky P, Henis YI, Rotter V: Mutant p53 attenuates the
SMAD-dependent transforming growth factor beta1 (TGF-
beta1) signaling pathway by repressing the expression of
TGF-beta receptor type II.  Mol Cell Biol 2007, 27:8228-8242.
49. Segade F, Daly KA, Allred D, Hicks PJ, Cox M, Brown M, Hardisty-
Hughes RE, Brown SD, Rich SS, Bowden DW: Association of the
FBXO11 gene with chronic otitis media with effusion and
recurrent otitis media: the Minnesota COME/ROM Family
Study.  Arch Otolaryngol Head Neck Surg 2006, 132:729-733.
50. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ:
Smad2 signaling in extraembryonic tissues determines ante-
rior-posterior polarity of the early mouse embryo.  Cell 1998,
92:797-808.
51. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA
Jr, Butel JS, Bradley A: Mice deficient for p53 are developmen-
tally normal but susceptible to spontaneous tumours.  Nature
1992, 356:215-221.